Aug. 3 at 2:10 PM
$NVCR "One interesting finding from the PANOVA-3 study that I didn’t expect is that we think of TTFields as a local treatment, but it also improved the rates of distant disease, meaning distant PFS. Somehow, a local treatment might reduce or prolong the time from development of distant metastases. We don’t [typically] see a local treatment having an effect on preventing or delaying the development of distant metastases. That’s worth noting. If there’s any possible synergy or effect on the immune system, that might indicate ways of combining [TTFields] with immunotherapy, for example. These are potential avenues for further exploration in the future."
